Error message

Strict warning: Only variables should be passed by reference in find_menu_item() (line 334 of /home/sensproj/srf-sens/sites/srf.org/modules/srf_site_structure/srf_site_structure.module).

New and Better Clinical Trials for Rejuvenation Biotechnologies

Posted by Michael Rae on July 31, 2013 | Chief Science Officer's Team

The need for disease-modifying therapies in Alzheimer's disease, and the strength of the case for aggregated beta-amyloid as a target, have recently driven substantial regulatory reform and innovations in clinical trial design to open up the path for faster and more effective human testing and approval of novel Alzheimer's therapeutics. The first fruits of these changes are a series of large, late-stage clinical trials of immunotherapies targeting the removal of beta-amyloid from the brain. These reforms and precedents open up the path for human testing and approval of future rejuvenation biotechnologies.

Amutha Boominathan: Moving vulnerable mitochondrial genes to the safety of the nucleus

Posted by iain.inkster on July 24, 2013 | SRF Research

We all know that mitochondria are the cell's "powerhouse" for energy. One interesting fact about these organelles is that they have their own DNA in addition to the nuclear DNA that we are all aware of. However, the mitochondrial DNA is prone to mutations due to constant exposure from reactive oxygen species because it is not encased in a nuclear envelope nor does it have efficient repair mechanisms to correct mutations as they occur. Amutha Boominathan explains how moving the mitochondrial genes to the nucleus, where it's safer to express them for function, would let mitochondria keep producing energy normally, even after mitochondrial mutations have occurred.

Jayanthi Vengalam: Engineering backup mitochondrial genes

Posted by iain.inkster on July 20, 2013 | SRF Research

Jayanthi Vengalam explains her work with the Mitochondrial Mutation team, with consequences for acute diseases such as diabetes, Parkinson's and Alzheimer's

Haroldo Silva: Lead OncoSENS Scientist Researches Telomere Lengthening and Cancer Pathways

Posted by Iain Inkster on July 01, 2013 | OncoSENS

Haroldo Silva explains why he joined OncoSENS team at the SRF Research Center and explains the role of telomere lengthening in cancer.

First Glimpse of Thymic Rejuvenation

Posted by Michael Rae on June 26, 2013 | Chief Science Officer's Team

Engineering of new thymus tissue is a key rejuvenation biotechnology, to prevent or reverse the dramatic rise in morbidity and mortality from infectious disease that begins in the seventh decade of life. SENS Research Foundation is supporting thymus engineering research at the Wake Forest Institute of Regenerative medicine. In an important first, researchers at UCSF have derived a simple thymus-like tissue transplant that gave promising signs of restoring the ability to help form mature T-cells.

New Staff Spotlight: Ehud Goldin, PhD

Posted by Iain Inkster on June 07, 2013 | Degradation of A2E

Dr. Ehud Goldin has recently joined SENS Research Foundation as head of the Research Center’s A2E degradation project. His work will be to enable the lysosomes of retinal pigment epithelial cells to degrade A2E...

CR in Nonhuman Primates: A Muddle for Monkeys, Men, and Mimetics

Posted by Michael Rae on May 06, 2013 | Chief Science Officer's Team

Two quarter-century long studies on the effects of Calorie restriction in nonhuman primates have come to opposing results. What do these results mean for the human translatability of CR, and the future of therapies to prevent and cure the diseases and disabilities of aging?

Cell Reprogramming Leaps Ahead: First Transplant of Primate Induced Pluripotent Cell-Derived Neurons into Donor Brain

Posted by Michael Rae on April 17, 2013 | Chief Science Officer's Team

"Reprogramming" of adult differentiated cells into pluripotent stem cells is an exciting method in biology that holds enormous promise for rejuvenation biotechnology. Now, for the first time, Dr. Su-Chun Zhang and coworkers at the University of Wisconsin-Madison have successfully generated neurons from reprogrammed nonhuman primate cells, transplanted them back into the same animal's brain, and seen them successfully and cleanly integrate into the local tissue.

SRF-Funded PhD Candidate Publishes

Posted by Daniel Kimbel on March 15, 2013 | Extra-mural Research

David Brindley, a SENS Research Foundation-funded PhD candidate at the University of Oxford, is the lead author on a new publication in the journal BioProcess International discussing the automation of cell therapy biomanufacturing.

SRF's Research Advisory Board Welcomes Dr. George Church

Posted by Ben Zealley on March 07, 2013 | Research Advisory Board

SENS Research Foundation is delighted to welcome Dr. George Church, Professor of Genetics at Harvard Medical School, to our Research Advisory Board. Our RAB plays a key role in our mission to change the way the world researches and treats age-related disease. By applying expertise from multiple relevant areas, the Board assures that efforts and resources are directed along the most promising avenues.

Project: Break Aging Arteries Free

Posted by Michael Rae on March 05, 2013 | GlycoSENS

SENS Research Foundation has established a new research center at Cambridge University and a collaboration with scientists at Yale University. The mission: develop new therapies to repair a critical form of molecular damage that drives the slow stiffening of the arteries with age. Such rejuvenation biotechnologies could prevent such deadly and disabling diseases of aging as stroke and kidney disease.

"Accelerated Aging:" Inspiration Beyond Equivocation

Posted by Michael Rae on September 26, 2012 | Chief Science Officer's Team

The preliminary results of a clinical trial for a disease of "premature aging" - Hutchinson-Gilford Progeria Syndrome (HGPS) - are hopeful and inspiring. However, they cannot directly inform the development of rejuvenation biotechnologies; although the symptoms of HGPS are similar to those observed in aging, there is no evidence to suggest that the underlying mechanism is pathologically significant in those not afflicted with the disease.

Pages